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Available online 22 October 2015Progression of metastatic castration-resistant prostate cancer
(mCRPC) is manifested as clinical progression (pain, skeletal-
related events, and other symptoms), radiological progression, or
increases in prostate-speciﬁc antigen (PSA) of 25% or more and
absolute increases of 2 ng/mL or more from the nadir.1 PSA ﬂare
occurs when there is an initial PSA increase of more than 25% after
the initiation of therapy, followed by a PSA decrease of at least 75%
compared to the maximum increase over baseline.2 Antiandrogen
withdrawal syndrome describes the phenomenon of a drop in PSA
with or without clinical improvement, following the withdrawal of
androgen receptor (AR) inhibitors or steroids.3
This presentation featured case studies of one patient with
antiandrogen withdrawal syndrome and two other patients with
PSA ﬂare. All three patients were treated with abiraterone. The PSA
responses from diagnosis and throughout treatment of the three
patients are captured in Fig. 1.* Corresponding author: Po Hui Chiang (cphtem@yahoo.com.tw).
http://dx.doi.org/10.1016/j.prnil.2015.10.003
p2287-8882 e2287-903XThe ﬁrst patient was an 80 year old with an initial PSA of
418.34 ng/mL who developed withdrawal syndrome after abir-
ateronewas discontinued (Fig. 1a). Studies have shown between 6%
e 23% of patients who discontinued abiraterone had antiandrogen
withdrawal response.4e6 This phenomenon is, however, not well
understood, and there is no evidence that clinicians should
routinely withhold further systemic therapy in mCRPC patients
progressing on abiraterone in anticipation of a withdrawal
syndrome.
The other patients in this case series were a 62 year old with
an initial PSA of 2,288 ng/mL (Fig. 1b), and a 76 year old with an
initial PSA 494.8 ng/mL (Fig. 1c). The ﬁrst patient developed PSA
ﬂare immediately after being treated with abiraterone, whereas
patient from the second case experienced a PSA rise at the sec-
ond month after an initial PSA response at ﬁrst month. In the
literature, it has been shown that between 6% and 8% of patients
who received abiraterone post-docetaxel developed PSA ﬂare.2,3
However, PSA ﬂare with abiraterone can occur regardless of
whether they received previous docetaxel chemotherapy. Pa-
tients who experienced PSA ﬂare had a longer median progres-
sion free survival (PFS) than those who did not have a PSA surge
(10.5 months vs. 6.3 months; p ¼ 0.0999).2 PSA ﬂare typically
lasts 3 e 12 weeks and does not negatively impact on survival.
Patients should be made aware of this effect to avoid the early
cessation of treatment.2
Fig. 1. PSA responses.
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